Targets › TNFRSF25
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Jul 2028.
Receptor for TNFSF12/APO3L/TWEAK. Interacts directly with the adapter TRADD. Mediates activation of NF-kappa-B and induces apoptosis. May play a role in regulating lymphocyte homeostasis. (UniProt, Q93038)
Open in Phaseline: the race on TNFRSF25, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shattuck Labs | SL-325 DR3 blocking antibody | TNFRSF25 | Phase 2 | Crohn's Disease; Healthy Volunteers | Jul 2028 |
Crohn's Disease (1) Healthy Volunteers (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.